{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Larisa Duffy, Caroline S Clarke, Gemma Lewis, Louise Marston, Nick Freemantle, Simon Gilbody, Rachael Hunter, Tony Kendrick, David Kessler, Michael King, Paul Lanham, Dee Mangin, Michael Moore, Irwin Nazareth, Nicola Wiles, Faye Bacon, Molly Bird, Sally Brabyn, Alison Burns, Yvonne Donkor, Anna Hunt, Jodi Pervin & Glyn Lewis.

Larisa Duffy ^1,*, Caroline S Clarke ^2,3, Gemma Lewis ¹, Louise Marston ^2,3, Nick Freemantle ^3,4, Simon Gilbody ⁵, Rachael Hunter ^2,3, Tony Kendrick ⁶, David Kessler ⁷, Michael King ^2,3, Paul Lanham ¹, Dee Mangin ^8,9, Michael Moore ⁶, Irwin Nazareth ^2,3, Nicola Wiles ⁷, Faye Bacon ¹, Molly Bird ¹, Sally Brabyn ⁵, Alison Burns ⁷, Yvonne Donkor ¹, Anna Hunt ⁶, Jodi Pervin ⁵, Glyn Lewis ¹

¹ Division of Psychiatry, University College London, London, UK
² Research Department of Primary Care and Population Health, University College London, London, UK
³ PRIMENT Clinical Trials Unit, University College London, London, UK
⁴ Comprehensive Clinical Trials Unit, University College London, London, UK
⁵ Department of Health and Social Care Sciences, University of York, York, UK
⁶ Primary Care Population Sciences and Medical Education, University of Southampton, Southampton, UK
⁷ Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
⁸ Department of Family Medicine, McMaster University, Hamilton, ON, Canada
⁹ Department of General Practice, University of Otago, Christchurch, New Zealand
^* Corresponding author Email: larisa.duffy@ucl.ac.uk

Declared competing interests of authors: Simon Gilbody reports serving on a number of funding committees: Health Technology Assessment (HTA) Efficient Study Designs 2 (2015–16), HTA End of Life Care and Add-on Studies (2014–16), HTA Funding Committee Policy Group (formerly CSG) (2017–20), HTA Clinical Evaluation and Trials Committee (2008–14), and HTA Commissioning Committee (2016–20). Tony Kendrick reports grants from the National Institute for Health Research (NIHR) during the conduct of the study. Glyn Lewis reports grants from University College London during the conduct of the study; personal fees from Fortitude Law (London, UK), outside the submitted work; and being a member of the Efficacy and Mechanism Evaluation Funding Committee (2011–16). Michael Moore reports grants from NIHR during the conduct of the study. Irwin Nazareth reports, as director of PRIMENT Clinical Trials Unit, core support funds from NIHR (that will be provided until 31 August 2022) for the Clinical Trials Unit, and was a member of the HTA Commissioning Sub-Board (2009–17), the HTA Primary Care Themed Call board (2013–14) and the HTA Commissioning Committee (2010–17).